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Abstract
Background: A number of osteoblastic meningiomas, primary osteosarcomas of the meninges,
and post-radiation osteosarcomas of the head have been reported. However, postradiation
dedifferentiation of meningioma into osteosarcoma has not been reported previously.
Case presentation: In 1987 a caucasian man, then 38 years old, presented with a pituitary
macroadenoma. He underwent a subtotal resection of the tumor and did well until 1990 when a
recurrent tumor was diagnosed. This was treated with subtotal resection of the tumor, followed
by radiation therapy for six weeks to a total of 54 Gy. He was considered "disease-free" for nearly
ten years. However, most recently in July 2000, he presented with a visual field deficit due to a
second recurrence of his pituitary macroadenoma, now with suprasellar extension. At this time, as
an incidental finding, a mass attached to the dura was noted in the left parietal hemisphere. This
dura–based mass had grown rapidly by January 2001 and was excised. It showed histological,
immunohistochemical, and electron microscopic features of malignant meningioma and
osteosarcoma with a sharp demarcation between the two components.
Conclusions: We report a rare case of a radiation induced dedifferentiation of meningioma into
osteosarcoma, which has not been reported previously.
Background
Meningiomas are benign tumors of the meningothelial
cells of the arachnoid. These tumors are usually attached
to the dura and can be found along the external surface of
the brain as well as within ventricular system, where they
arise from the stromal arachnoid cells of the choroid plex-
us. Although intracranial tumors as a whole show a higher
prevalence in males than in females, meningiomas have a
2:1 female-to-male ratio. Meningiomas are rare in chil-
dren and even more rare in infants. They are usually soli-
tary and their presence at multiple sites, especially in
association with acoustic neuromas or glial tumors, sug-
gests a diagnosis of type 2 neurofibromatosis. Several his-
tological types are described. These include syncytial,
fibroblastic, transitional, psammomatous, microcystic,
papillary, glycogen-rich, cartilaginous, osteoblastic, and
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malignant [1]. The wide spectrum of different types of
meningiomas is most likely due to their dual epithelial
and mesenchymal properties. Osteoblastic meningiomas,
primary osteosarcomas of the meninges, and post-radia-
tion osteosarcomas of the skull have been reported in past
[2–8]. However, postradiation dedifferentiation of men-
ingioma into osteosarcoma has not been reported previ-
ously.
Case presentation
This 52-year-old white male was initially diagnosed with
a pituitary macroadenoma at the age of 38 years in March
1987. He underwent a subtotal resection of this tumor via
a trans-sphenoidal approach. In early 1990, he noted
some light spots within his visual fields. Further testing
showed bitemporal hemianopia. Imaging studies revealed
a recurrence of his pituitary adenoma. At that time no
dura based tumor was detectable. In May 1990, he was
treated with subtotal resection of the tumor via a right
frontal approach, followed by radiation therapy. The reg-
imen consisted of 1.8 Gy in 30 fractions through 220 de-
gree arc using 4 mV photons to a total dose of 54 Gy.
The patient experiened progressive visual field deficit
again in July 2000. Magnetic resonance imaging (MRI)
scan of August 2000 revealed a 2 cm pituitary macroade-
noma with suprasellar extension. At this time a small,
dura based mass measuring 1.3 cm in greatest dimension
was incidentally noted in the left parietal hemisphere (Fig.
1a). It did not involve the skull and was interpreted as
meningioma. This dura – based mass was initially fol-
lowed, but it demonstrated dramatic progression reaching
to the size of 3.5 cm in the MRI scan of January 2001 (Fig.
1b). It was resected and submitted for histopathological
evaluation. Following this resection, the patient received a
second course of radiation therapy to the operative bed
with a 2–3 cm margin. A total dose of 54 Gy in 27 frac-
tions of 2 Gy was given. However, the tumor recurred after
8 months and patient succumbed to the disease 10
months after that recurrence. Autopsy was not performed.
Methods
Hematoxylin-eosin stained formalin-fixed paraffin-embe-
ded tissue sections were studied by light microscopy. Im-
munohistochemical stains were performed on formalin-
fixed paraffin-embedded tissue sections using streptavidin
horseradish peroxidase method. The details of antibodies,
clones, and pretreatments are shown in the Table 1. Ap-
propriate positive and negative controls were set up at the
same time.
Figure 1
MRI of head. a: In August 2000 second recurrence of pituitary adenoma was detected with incidental 1.3 cm meningioma
(arrow). B: By January 2001 the meningioma (arrow) grew rapidly and reached 3.5 cm in 5 months.
a bBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/34
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Electron microscopy (EM) was performed by retrieving
cores of tissue from respective areas of the tumor in the
paraffin block. The cores were deparaffinized, hydrated,
and brought to 0.1 M Cacodylate buffer followed by 1%
Osmium tetraoxide. They were transferred through as-
cending grades of methanol to absolute methanol, fol-
lowed by acetonitrile-epon sequence for final epon
embedding and sectioning. Ultrathin sections were
stained with lead citrate for electron microscopic exami-
nation after studying representative thick sections.
Results
The tumor resected in January 2001 was attached to a por-
tion of the dura. It measured 3.5 × 3.5 × 1.5 cm and was
ovoid, rubbery, with external bosselations. The cut surface
was glistening gray white with focal areas of brown discol-
oration.
Microscopy revealed two distinct histological patterns
with sharp demarcation (Figure 2a). One area showed fea-
tures of malignant meningioma with spindle cells ar-
ranged in whirls with foci of necrosis (Figure 2b). Nuclei
showed moderate atypia with 13 mitotic figures per 10
high power fields (field diameter 0.35 mm). Numerous
psammoma bodies were noted in a section from the pe-
ripheral area showing fibroblastic pattern with spindle
cells and bland nuclei.
Another area adjacent to the meningioma showed fea-
tures of osteosarcoma with scattered osteoclast – type gi-
ant cells in the background of high grade spindle cells
with clear to vacuolated eosinophilic cytoplasm (Figure 2c
and 3) and 26 mitotic figures per 10 high power fields
(Figure 3). These cells were arranged in short fascicles and
were separated by numerous small caliber blood vessels
and focal delicate intercellular osteoid trapping the tumor
cells (Figure 2c). Some areas showed medium sized blood
vessels with stag-horn pattern. Numerous scattered apop-
totic bodies with focal large areas of necrosis were present.
These two patterns were sharply demarcated with a dis-
tinct line of osteoid lamellae separating them (Figure 2a).
The osteosarcoma component was surrounded by menin-
gioma, which was seen as thin rim in some places at the
periphery highlighted further in the section immunos-
tained for S-100.
The tumor cells in the meningioma component were im-
munoreactive for vimentin, EMA (Figure- 4a), and S-100
protein. They showed immunoreactivity for progesterone
receptor in occasional nuclei and were non-immunoreac-
tive for CD34, estrogen receptor, and cytokeratin AE1/
AE3. The tumor cells in the osteosarcoma component
were non-immunoreactive for all these immunomarkers,
except vimentin (Table 1).
Reticulin stain showed a complex network around indi-
vidual tumor cells and small groups of cells in the osteosa-
rcoma, whereas it was sparse and present only in some
areas interspersed between groups of tumor cells in the
meningioma component (Figure- 4b &4y). Meningioma
component showed 12% nuclei immunoreactive for Ki-
67, as compared to 28% in the osteosarcoma component
(Figure- 4c and 4z). CD34 highlighted the marked differ-
ences in the vascularity of the two components with mean
Table 1: Immunohistochemical profile of both components of the tumor.
Immuno-marker Clone* Dilution Pretreatment / Target retrieval Meningioma component Osteosarcoma component
Vimentin Vim 3B4 1:200 Proteinase K enzyme 1:1 with TRIS 
buffer fro 4 min
Immunoreactive Immunoreactive
CD34 QBEnd 10 1:25 10 mM citrate buffer, pH6 for 30 
min with 20 min cool down
Non-immunoreactive Non-immunoreactive
Pan-cytokeratin Polyclonal 1:50 Proteinase K enzyme 1:1 with TRIS 
buffer for 4 min
Non-immunoreactive Non-immunoreactive
S-100 protein Polyclonal 1:300 Proteinase K enzyme 1:1 with TRIS 
buffer fro 4 min
Immunoreactive Non-immunoreactive
Estrogen receptor ID5 1:75 10 mM citrate buffer, pH6 for 30 
min with 20 min cool down
Non-immunoreactive Non-immunoreactive
Progesteron receptor PgR636 1:50 10 mM citrate buffer, pH6 for 30 
min with 20 min cool down.
Focally immunoreactive Non-immunoreactive
EMA E29. (3). 1:50 No target retrieval Immunoreactive Non-immunoreactive
Ki-67 MIB-1 1:50 10 mM citrate buffer, pH6 for 30 
min with 20 min cool down
12% nuclei immunoreactive 28% nuclei immunoreactive
*All antibodies were from Dako, Carpinteria, CA.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/34
Page 4 of 6
(page number not for citation purposes)
vascular count of 3 vessels per 200 tumor cells in the men-
ingioma component and 18 vessels per 200 tumor cells in
the osteosarcoma component.
EM confirmed the histological and immunohistochemi-
cal findings. EM of meningioma component showed char-
acteristic features. The most prominent was
interdigitation of adjacent cells often punctuated by
desmosomes [9]. EM of osteosarcoma component re-
vealed matrix with scattered collagen fibers and focal cal-
cium deposits [10].
The second recurrence of the dedifferentiated meningi-
oma, 8 months after the initial resection in Januaary 2001,
showed the histomorphology of osteosarcoma similar to
the first resection with added histomorphological spec-
trum of chondroblastic differentiation (Figure 3b).
Discussion
Meningiomas are usually benign tumors of pia-arachnoid
and are generally seen in the 5th and 6th decades. Several
etiologic factors, including ionizing radiation, head inju-
ry, hormones, genetic factors, and viruses are suggested in
the literature [9,11]. Osteosarcomas of the head have been
associated with radiation therapy without any clear evi-
Figure 2
Hematoxylin and eosin stained sections of the tumor. a. Meningioma component (1) was distinctly and sharply demarcated by
prominent osteoid trabeculae (2) from the adjacent high grade osteosarcoma (3). b. Meningioma with intact whirling pattern.
c. Osteosarcoma was high grade with pleomorphic nuclei and high mitotic rate with foci of fine osteoid (4), (a, b and c- H&E







a.  Higher magnification of osteosarcoma with numerous
mitotic figures and ostoclastic giant cells. b. Osteosarcoma
with areas of chondroblastic differentiation in the recurrence
after 8 months (a and b- H&E stain, a- X20, b- X40).
a bBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/34
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dence of the relationship between the dose of radiation
and rate of osteosarcomas [2–5,7,8]. Some authors regard
primary osteosarcomas of meninges as a malignant coun-
terpart of osteoblastic meningiomas [6].
We present a case of postradiation dedifferentiation of a
meningioma into osteosarcoma in a 52-year-old man
treated with radiation therapy for recurrent pituitary ade-
noma 10 years before. The tumor was detected incidental-
ly by MRI performed during the investigation for the
second recurrence of the adenoma in August 2000 (Figure
1a). During the follow up, by January 2001, this tumor
had dramatically progressed in size (Figure 1b). The ovoid
tumor measured 3.5 cm and was attached to the dura. His-
tologically, it was remarkable with two distinct patterns.
The histomorphology (Figure 2,3,4), ultrastructure, and
immunoprofile of the tumor cells (Table 1, Figure 4a
&4x,4c &4z) in these two areas were consistent with men-
ingioma and osteosarcoma, respectively.
The two areas were sharply demarcated by a well defined
line composed of poorly formed osteoid trabeculae. The
osteosarcoma component was entirely surrounded by
meningioma component, which in some areas was re-
duced to a thin rim at the periphery. A sharp demarcation
line between high grade (osteosarcoma) and low grade
(meningioma) component was consistent with dediffer-
entiation [12].
Postradiation dedifferentiation of a meningioma has not
been reported previously, although postradiation sarco-
ma of skull following radiation therapy for partially re-
sected meningioma has been reported [5]. The time span
reported in the literature between the radiation therapy
and appearance of a post-radiation sarcoma varies from 5
years to decades. Chang et al [13] and Bernstein et al [14]
have reported latency periods of 8 and 10 years, respec-
tively. In this case, the time span between initial radiation
therapy and emergence of meningioma with dedifferenti-
ation into osteosarcoma was approximately 10 years. The
tumor was not attached to the skull bones and recurred af-
ter 8 months. The recurrence demonstrated all the features
of osteosarcoma along with additional histomorphologi-
cal pattern of chondroblastic differentiation.
Figure 4
Comparison of meningioma and osteosarcoma components of the tumor. Meningioma was immunoreactive for EMA (a), with
none to scant reticulin (b), and low proliferative activity with few Ki-67 positive nuclei (c). Osteosarcoma was non-immunore-
active for EMA (x), with prominent reticulin around single cells and small groups of cells (y), and high proliferative activity with
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The features considered to be helpful in categorizing this
tumor as dedifferentiated, included sharp demarcation
line, prominent variability in histological appearance,
loss of surface markers, and high Ki-67 index. Based on
the gross, histological, and immunophenotypic features,
we interpreted this tumor as a rare case of postradiation
dedifferentiation of meningioma into osteosarcoma. A
rare possibility of collision of meningioma and osteosar-
coma of meninges can be ruled out by the finding that os-
teosarcoma component was completely surrounded by
meningioma component. Collision tumors are uncom-
mon, and dedifferentiation is relatively common in many
low grade tumors [12]. In this case dedifferentiation is fa-
vored due to a distinct line of separation between menin-
gioma (low grade component) and osteosarcoma (high
grade component) showing high grade morphology with
loss of immunoreactivity to various immunomarkers,
high Ki-67 index, and increased mean vascular density
(Figure 2,3,4).
Conclusions
We report a rare case of dedifferentiated meningioma. The
dedifferentiation appears to be secondary to radiation
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